Interaction between terbutaline and ethyl 2-(4'-carboxybenzamido)-4-propionamidobenzoate sodium salt in tracheal smooth muscle relaxation of guinea pig.

Article

Author: Takagi, K ; Yin, K ; Yamaki, K ; Satake, T ; Suzuki, R

Ethyl 2-(4-carboxybenzamido)-4-propionamidobenzoate sodium salt (AM-682) is a new, orally active, antiallergic compound which has been reported to inhibit the release of histamine and leukotrienes from mast cells more than disodium cromoglycate (DSCG) or Tranilast. In the present study, the interaction between terbulatine, a beta 2-receptor agonist, and AM-682 or met-A, AM-682's main metabolite in humans, in guinea pig tracheal smooth muscle was investigated by measuring the isometric tension in vitro. Combinations of terbutaline and AM-682 or met-A produced more than additive relaxant effects. Comparing the combined effects with the calculated algebraic sums of single drug effects, the differences were statistically significant for terbutaline 10(-9) mol/l and AM-682 3 X 10(-6) mol/l, 10(-5) mol/l and 3 X 10(-5) mol/l (p less than 0.01) or met-A 3 X 10(-6) mol/l, 10(-5) mol/l (p less than 0.05) on the spontaneous tone of tracheal smooth muscle, and for terbutaline 10(-9) mol/l and AM-682 10(-5) mol/l (p less than 0.01), 3 X 10(-5) mol/l (p less than 0.05) on the tension of tracheal smooth muscle induced by 5.4 X 10(-7) mol/l carbachol. Thus the tracheal smooth muscle relaxant effects of AM-682 and the beta 2-receptor agonist terbutaline were synergistic. It is suggested that the combination of AM-682 and a beta 2-receptor agonist, rather than administration of each drug separately, may provide the therapeutic advantage in the treatment of bronchial asthma.

01 Jan 1990·Arzneimittel-Forschung

Effect of the new anti-allergic compound ethyl 2-(4'-carboxybenzamido)-4-propionamidobenzoate sodium salt on human neutrophil superoxide production.

Article

Author: Takagi, K ; Satake, T ; Furui, H ; Suzuki, K ; Kaneko, M

The effect of the new orally active antiallergic compound ethyl 2-(4'-carboxybenzamido)-4-propionamidobenzoate sodium salt (AM-682) and its main metabolite (met-A) were evaluated on respiratory burst in isolated human polymorphonuclear neutrophils (PMN). Both compounds exhibited inhibitory effect with concentration dependency on the n-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O-2) production by human PMN. The inhibitory activity of met-A (IC50 1.1 mumol/l) was higher than that of AM-682 (IC50 85 mumol/l). By contrast, these compounds affected neither PMN O-2 production induced by phorbol 12-myristate 13-acetate (PMA) nor extracellular O-2 generation by the reaction of xanthine oxidase with hypoxanthine. These results indicate that the effects of these compounds act specifically on the generation of O-2 and is not simply a scavenger of O-2. This anti-inflammatory effect may also be beneficial in the treatment of asthma.

100 Deals associated with AM-682

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 3	JP	Chugai Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AM-682

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation